Telehealth & Digital Health

Skanska's massive Karlstad hospital project promises a high-tech future, but can a building solve deep-seated healthcare system challenges like staff shortages?

A new pact between BioSTL and the UK's NHS is set to make St. Louis a prime U.S. launchpad for health tech, turning global innovation into local impact.

One company's focus on convenience just earned it top marks. We explore how streamlined ordering and tech-savvy verification are reshaping the vision care industry.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

A major data breach at Ohio Living exposes sensitive patient and employee data, echoing a past failure and signaling a deepening crisis for the entire sector.

Top federal ministers, Canada's new CPHO, and the Fentanyl Czar will unveil updated opioid data and actions. Will it be enough to turn the tide on a crisis?

Abbott's 410th dividend isn't just about shareholder returns. It’s a signal of the financial stability fueling a vast, invisible network of health tech.

A silent barrier in diabetes care, 'clinical inertia,' leaves patients at risk. New research shows how empowering pharmacists with targeted education can turn the tide.

In an era of digital sieges on healthcare, one small hospital's CEO is rewriting the playbook, proving that resilience isn't a matter of size but strategy.

A Solana memecoin raised nearly $100k for breast cancer prevention, revealing a potentially resilient new model for creating sustainable social impact.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

A new book signals a major shift in the veterinary industry, where AI-driven strategy is becoming the key to survival and growth in a competitive market.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

With its new Series A, Aton Health isn't just growing; it's validating a model where research is seamlessly integrated into routine patient care.

A new survey shows Asians value independence over inheritance, yet a massive gap between intention and action threatens to derail their plans for self-reliance.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?